Darbepoetin alfa and chronic kidney disease [3]

New England Journal of Medicine

Volumn 362, Issue 7, 2010, Pages 654-

  Hampl, Hannelore ^a   Kovesdy, Csaba P ^b   Kalantar Zadeh, Kamyar ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; CHRONIC KIDNEY DISEASE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEPLETION; IRON STORAGE; IRON THERAPY; KIDNEY FUNCTION; LETTER; MORTALITY; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTOSIS;

EID: 77149120481     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Hampl H, Riedel E. Cardiac disease in the dialysis patient: good, better, best clinical practice. Blood Purif 2009;27:99-113.
2. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008;52:727-36.
3. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000.
4. Vaziri ND. Thromobocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency. Am J Kidney Dis 2009;53:733-6.